Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Symtomatisk och systemisk aterosklerotisk plackaktivitet hos patienter med perifer artärsjukdom med användning av ny avbildningsteknik (SISYPHUS)

17 september 2026 uppdaterad av: University of Edinburgh

Symptomatisk och systemisk aterosklerotisk plackaktivitet hos patienter med perifer artärsjukdom med ny avbildningsteknik

The goal of this observational study is to characterise the relationships between inflammation, microcalcification and thrombus activity in atherosclerotic plaques in peripheral and systemic vascular territories in patients with symptomatic peripheral arterial disease.

Studieöversikt

Detaljerad beskrivning

In peripheral arterial disease (PAD), arteries in the lower body can become narrowed and develop blockages due to a process called atherosclerosis, leading to reduced blood flow to the lower limbs. Symptoms can range from mild cramping pain in legs on walking, to loss of parts of the leg. Patients with PAD are also at a high risk of blockages in other arteries in the body that can lead to problems such as heart attacks and strokes. Despite improvements in medical treatments and surgery, the outlook for patients with PAD has not improved.

Further information is required to understand the relationships between the processes that lead to narrowing and blockages (atherosclerosis) of the arteries and if they behave the same in different parts of the body. This can help to identify targeted treatments to reduce the risk of the disease getting worse and avoid heart attacks and strokes.

In this study investigators plan to recruit 100 people with symptomatic PAD to undergo a series of whole body PET-CT and CT angiogram scans using different tracers targeting the processes involved in atherosclerosis. Investigators will aim to co-enrol patients taking part in the LEADER-PAD study (NCT04774159).

Studietyp

Observationell

Inskrivning (Beräknad)

100

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Allison c Winarski, MBChB, MRCS(Ed)
  • Telefonnummer: +447495905258
  • E-post: awinarsk@ed.ac.uk

Studera Kontakt Backup

Studieorter

    • Midlothian
      • Edinburgh, Midlothian, Storbritannien, EH16 4SA
        • Rekrytering
        • Royal Infirmary of Edinburgh
        • Kontakt:
          • Allison C Winarski, MBChB MRSC(Ed)
          • Telefonnummer: +447495905258
          • E-post: awinarsk@ed.ac.uk
        • Kontakt:
        • Underutredare:
          • Allison C Winarski, MBChB MRCS (Ed)
        • Huvudutredare:
          • Rachael O Forsythe, MBChB, PhD, FRCS (Vascular)
        • Underutredare:
          • David E Newby, BSc (Hons)PhD BM DM DSc FRCP

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Patients will be prosectively recruited from vascular outpatient clinics and inpatient wards.

Beskrivning

Inclusion Criteria:

  • Male or female aged > 18 years

  • Symptomatic atherosclerotic peripheral artery disease;

    • Intermittent claudication; with ankle/arm blood pressure ratio <0.90 or artery stenosis >50% in addition to at least one of the following;

      • >1 vascular bed affected by atherosclerosis
      • Diabetes
      • Heart failure
      • Chronic kidney disease (eGFR < 60 mL/min/1.73 m2)
    • Rest pain or necrosis of limb or gangrene of limb

    • Revascularization defined as limb bypass surgery or endovascular revascularization procedures (irrespective of the specific device used), including percutaneous transluminal angioplasty/stent of iliac or infra-inguinal arteries or extra-anatomical bypass surgery

    • Leg or foot amputation for arterial vascular indications

  • Ability to give written or verbal informed consent

Exclusion Criteria:

  • Contraindication to colchicine or iodinated contrast
  • Long term requirement for colchicine for another clinical indication
  • Active diarrhoea
  • Recent lower limb revascularisation for symptomatic disease (<6 weeks)
  • Renal failure (glomerular filtration rate <30 mL/min/1.73 m2)
  • Cirrhosis or severe chronic liver disease
  • Women who are pregnant or breast-feeding
  • Women of child-bearing potential not protected by reliable contraception or is planning conception during the study
  • Current or planned long term use of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics (apart from azithromycin)
  • Patients deemed unlikely to return for follow up
  • Life expectancy <1 year
  • Inability or unwilling to give informed consent

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Patienter med symtomatisk perifer artärsjukdom

Targeting vascular inflammation

Targeting thrombus activity

Targeting vascular microcalcification

To determine anatomical and morphological atherosclerotic plaque characteristics

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Quantification of PET tracer uptake of [68Ga]DOTATATE, [18F]GP1 and [18F]NaF in the symptomatic lower limb(s)
Tidsram: From baseline imaging until completion imaging at 1 year

The 3 primary endpoints will be the location and degree of:

  1. inflammation: uptake of [68Ga]DOTATATE
  2. calcification: uptake of [18F]NaF
  3. thrombus activity: uptake of [18F]GP1 in peripheral arterial disease affecting the lower limbs. This will be determined by the degree of tracer standardised uptake values (SUVs) at the site of the symptomatic atherosclerotic plaque.
From baseline imaging until completion imaging at 1 year

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Quantification of PET tracer uptake of [68Ga]DOTATATE, [18F]GP1 and [18F]NaF in remote arterial territories
Tidsram: From baseline imaging until completion imaging at 1 year

The secondary outcome measures will be the location and degree of inflammation, calcification and thrombus activity in remote arterial territories, including the coronary arteries, cerebral arteries, aorta and mesenteric vessels, as determined by SUVs of [68Ga]DOTATATE, [18F]NaF and [18F]GP1, respectively.

From baseline imaging until completion imaging at 1 year
CT plaque morphology
Tidsram: From baseline imaging to completion imaging at 1 year

Investigators will characterise CT plaque morphology (total, calcified, non-calcified and low-attenuation plaque) in peripheral and systemic arterial beds and compare this to areas of [68Ga]DOTATATE, [18F]GP1 and [18F]NaF uptake.

From baseline imaging to completion imaging at 1 year
The association between patient risk factors for cardiovascular disease and PET tracer uptake
Tidsram: Frome baseline imaging to completion imaging at 1 year

Investigators will explore the association between patient risk factors for cardiovascular disease (hypertension, diabetes, smoking) and the degree of [68Ga]DOTATATE, [18F]GP1 and [18F]NaF uptake as quantified by standard uptake values (SUVs). This will be measured by odds ratio (OR) with 95% confidence interval (CI) for each risk factor-tracer combination.

Frome baseline imaging to completion imaging at 1 year
The progression of microcalcification, as defined by [18F]NaF uptake, to macrocalcification.
Tidsram: From baseline imaging to completion imaging at 1 year

Investigators will also aim to characterise the relationship between microcalcification progressing to calcification and the uptake of [18F]NaF. This will be assessed using baseline and follow-up [18F]NaF PET-CT SUVs and their correlation with calcified regions on CT angiography.

From baseline imaging to completion imaging at 1 year

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Major adverse cardiovascular events (MACE) and major adverse limb events (MALE)
Tidsram: From baseline imaging to completion imaging at 1 year

Exploratory endpoints will include major adverse cardiovascular events (acute myocardial infarction, stroke or cardiovascular death) and major adverse limb events (revascularisation or lower limb amputation) as well as death from any cause.

From baseline imaging to completion imaging at 1 year

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Rachael O Forsythe, MBChB, PhD, FRCS (Vascular), University of Edinburgh

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

31 juli 2025

Primärt slutförande (Beräknad)

1 juli 2028

Avslutad studie (Beräknad)

1 juli 2029

Studieregistreringsdatum

Först inskickad

15 september 2025

Först inskickad som uppfyllde QC-kriterierna

11 mars 2026

Första postat (Faktisk)

16 mars 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera